

# Musculoskeletal pain is associated with a long-term increased risk of cancer and cardiovascular-related mortality

J. McBeth<sup>1</sup>, D. P. Symmons<sup>1</sup>, A. J. Silman<sup>1,2</sup>, T. Allison<sup>3</sup>, R. Webb<sup>4</sup>, T. Brammah<sup>5</sup> and G. J. Macfarlane<sup>6</sup>

**Objectives.** To test the hypothesis that individuals with regional and widespread pain disorders have an increased risk of mortality.

**Methods.** We conducted a prospective cohort study of 4515 adults. Subjects were an age- and sex-stratified sample who had participated in a population study of pain occurrence during 1996. Based on those reports subjects were classified as having no pain, regional pain or widespread pain. All subjects were identified on the National Health Service Central Register and followed up until April 2005, a total of 8.2 yrs, at which time information was obtained on vital status, and if applicable, date and cause of death. The relationship between pain status and subsequent death is expressed as mortality rate ratios with 95% CIs, adjusted for age, gender, ethnicity and practice.

**Results.** A total of 35.2% reported regional pain and 16.9% satisfied criteria for widespread pain. In comparison with those without pain, there was a 20% and 30% increased risk of dying over the follow-up period among subjects with regional and widespread pain, respectively. The specific causes of death in excess were cancer and cardiovascular disease. In addition, the mortality risk from both cancer and cardiovascular deaths was found to increase as the number of pain sites that subjects reported increased.

**Conclusions.** This study supports a previous observation that persons with regional and widespread pain are at an increased risk of cancer death. Possible mechanisms should be explored.

**KEY WORDS:** Pain, Musculoskeletal, Mortality, Cancer, Cardiovascular, Epidemiology, Population-based study, Prospective, Mechanisms.

## Introduction

Pain that is widespread throughout the body is the cardinal symptom of fibromyalgia [1]. Although the aetiology of this syndrome is unclear a number of factors including trauma [2], genetic factors [3–5] and psychological factors [6] have been implicated in symptom onset. In the short term following onset, the majority of cases of chronic widespread pain [7] and fibromyalgia [8] tend to persist and are associated with a loss of function and high levels of disability [9]. The long-term health consequences of having chronic widespread pain is however unclear.

We have previously demonstrated that subjects who reported widespread pain in a population-based survey [10] had an increased risk of mortality compared with those reporting no pain over the following 9 yrs. Although deaths from external causes (suicides and accidents) were increased in those with widespread pain, these deaths were rare and the excess mortality was almost entirely explained by deaths from cancer. Similar relationships, albeit slightly attenuated, were observed for those subjects reporting regional pain symptoms. A further analysis of the same data set revealed that widespread pain was associated with both cancer onset (incidence) and subsequent reduced survival [11]. The strongest relationship was with breast and prostate cancer, with smaller effects for gastrointestinal and lung cancer. These relationships persisted after adjustment for age, gender, social class and smoking. Although intriguing, this was

the first report of such a relationship and subsequent analyses of data relating to chronic pain in general [12] or ‘widespread’ pain [13, 14] have been equivocal. These discrepancies may be explained by differences in the cohorts studied or uncontrolled confounding effects. The observation requires replication in a separate population-based cohort before investigating mechanisms that potentially link regional and widespread pain and mortality. A cohort study conducted in 1996 in the North West of England afforded a unique opportunity to do so.

The aim of the current study was to determine whether our initial observation of a higher rate of cancer mortality among subjects with regional and widespread pain would be confirmed in a new general population sample.

## Methods

### Study design

The study was a population-based cross-sectional study of pain and has been described in detail elsewhere [15, 16]. In brief, subjects aged 16 yrs and over were recruited from three general practices in North West England. The Tameside and Glossop Research Ethics Committee approved the original study. The follow-up study was approved by the North West Multi-centre Research Ethics Committee and the University of Manchester Committee on the Ethics of Research. The Office for National Statistics approved the provision and use of death registration data. An age- (16–44, 45–64, 65–74 and 75+ yrs) and sex-stratified random sample of 750 subjects from each stratum was identified from the combined practice lists. Of those, 86 subjects were excluded from the original sample selected as they had recently died or were terminally ill and were replaced with the next eligible patient on the list. Each of the remaining subjects was mailed a postal questionnaire between January and November 1996 with non-responders being sent a reminder postcard 2 weeks after the mailing of the initial questionnaire and a further copy of the questionnaire 2 weeks later. A total of 4515 subjects returned the questionnaire, giving a response rate of 78.5% after removing from the denominator those subjects who had moved and were unlikely to have received the study questionnaire ( $N = 228$ ). Younger subjects and men were more likely not to participate.

<sup>1</sup>Arthritis Research Campaign (ARC) Epidemiology Unit, Epidemiology Research Group, Research School of Translational Medicine, University of Manchester, Manchester, <sup>2</sup>ARC House, Chesterfield, <sup>3</sup>National Primary Care Research and Development Centre, <sup>4</sup>Psychiatry and Health Methodology Research Groups, School of Community Based Medicine, University of Manchester, Manchester, <sup>5</sup>Tameside General Hospital, Ashton-Under-Lyne and <sup>6</sup>Aberdeen Pain Research Collaboration (Epidemiology Group), Department of Public Health, University of Aberdeen, School of Medicine, Aberdeen, UK.

Submitted 7 January 2008; revised version accepted 6 October 2008.

Correspondence to: J. McBeth, Arthritis Research Campaign (ARC) Epidemiology Unit, Epidemiology Research Group, Research School of Translational Medicine, Stopford Building, University of Manchester, Manchester, M13 9PT, UK. E-mail: john.mcbeth@manchester.ac.uk

### Study questionnaire

The study questionnaire gathered demographic information: age, gender and ethnicity. In the questionnaire, subjects were asked whether they had experienced any pain in the past month that had lasted for 1 week or longer. Those who answered 'yes' were asked to indicate the site of their pain on a blank body manikin. Subjects' reports were scored using a 10-section coding schedule with each section being scored 0 'pain not present' or 1 'pain present'.

### Deprivation

Postcodes were available for each person who returned a health survey. Each subject was assigned a Townsend score (a measure of material deprivation) based on their postcode [17]. The Townsend score includes four variables, derived from the Census: unemployment (percentage of economically active residents [aged 16+ yrs] who are unemployed), overcrowding (percentage of private households with more than one person per room), non-home ownership (percentage of private households that are not owner occupied) and lack of car ownership (percentage of private households that do not own a car). The score is calculated by summing the standardized scores for each variable (the unemployment and overcrowding percentages must first be transformed using the natural log function). Scores >0 indicate higher levels of deprivation, and negative values indicate less deprived areas.

### Classification of pain status

On the basis of their pain reports, subjects were classified into one of three groups: those reporting 'no pain'; those reporting pain which did not satisfy criteria for widespread pain were classified as having 'regional pain'; and those reporting pain that satisfied the ACR criteria for widespread pain used in their classification of fibromyalgia [1]. To satisfy these criteria subjects must have reported pain on the left and right hand sides of the body, above and below the waist, and pain in the axial skeleton. In addition, we were interested to examine the relationship between increasing number of pain sites reported by subjects and the risk of mortality. To do so we summed the total number of sites in which subjects had reported pain constructing a 'pain total score' variable with scores ranging from 0 to 10.

### Subject follow-up and ascertainment of vital status

All subjects were followed up until either death or 30 April 2005, a total of 8 yrs of follow-up for those still alive. Demographic details of all subjects were sent to the National Health Services Central Register, which holds information on all subjects who have registered with a general practitioner. In the United Kingdom, 95% of subjects are registered with a general practitioner. All subjects in the current study were successfully identified and were 'flagged' enabling them to be tracked over time. The NHS register is linked to official records that allow vital status and, if dead, cause of death to be determined. Underlying cause of death was coded using the International Classification of Diseases (ICD) 10th revision [18].

### Statistical analysis

The number of person-years at risk of dying was calculated from the date of subjects returning their baseline questionnaire to either the end of the follow-up period (30 April 2005) or if the person had died, the date of death. The mortality rates in the 'no pain', 'regional pain' and 'widespread pain' groups were then calculated. We then calculated standardized mortality ratios (SMRs), i.e. the ratio of observed to expected number of deaths, standardized to the population of North West England. SMRs were calculated

TABLE 1. Characteristics of study population

	No pain (n=1993)	Regional pain (n=1590)	P*	Widespread pain (n=761)	P**
Age, mean (SD), yrs	56.0 (19.9)	62.5 (17.3)	0.00	64.7 (15.4)	0.00
Gender, female, n (%)	951 (47.7)	825 (51.9)	0.01	456 (59.9)	0.00
Practice, n (%)					
1	715 (46.9)	545 (35.8)	0.08	264 (17.3)	0.01
2	602 (42.6)	536 (37.9)		275 (19.5)	
3	676 (48.1)	509 (36.2)		222 (15.8)	
Ethnic group, n (%) <sup>a</sup>					
White	1889 (95.7)	1514 (96.4)	0.75	719 (95.5)	0.76
Afro-Caribbean	38 (1.9)	30 (1.9)		15 (2.0)	
Indian	21 (1.1)	12 (0.8)		10 (1.3)	
Pakistani	6 (0.3)	2 (0.1)		2 (0.3)	
Bangladesh	9 (0.5)	5 (0.3)		6 (0.8)	
Chinese	4 (0.2)	2 (0.1)		0 (0.0)	
Other	7 (0.4)	5 (0.3)		1 (0.1)	

<sup>a</sup>Excludes subjects with missing data. \*Regional pain compared with no pain, P-value by chi-squared test. \*\*Widespread pain compared with no pain, P-value by chi-squared test.

for the whole study population and separately by pain status at baseline. The number of expected deaths was obtained by multiplying the numbers of person-years at risk by the age, gender and calendar year-specific mortality rates for the North West England population obtained from the Office for National Statistics. For each SMR, a 95% CI was calculated assuming that the number of deaths followed a Poisson distribution. The relationship between pain status and subsequent all-cause mortality was quantified using a Cox proportional hazards model. Similar analyses were conducted to examine the relationship with cause-specific mortality. For all analyses the 'no pain' group was classified as the referent group. To explore the relationship between the number of pain sites reported and mortality the total pain score variable described above was entered as a continuous variable. To take account of the unequal probability stratified sampling design, age-sex stratum-specific sampling probability weights were applied to each subject and 'weighted' Cox proportional hazards models were fitted [19]. All models were adjusted for the potential confounding effects of age, gender, practice, Townsend score (in quartiles) and ethnicity (as defined in Table 1). Our results are presented as mortality rate ratios (MRRs) with 95% CI. None of the estimated models violated the assumption of proportionality over time.

### Role of the funding source

The study sponsors did not influence the study design, collection, analysis and interpretation of data, nor the writing of the report and decision to submit the article for publication.

### Results

Of the 4515 subjects who completed the baseline survey, 2331 (51.6%) were females. Pain status was not available for 171 (3.8%). Of the remaining subjects, 1993 (44.1%) reported no pain, 1590 (35.2%) had regional pain and 761 (16.9%) were classified as having widespread pain (Table 1). Compared with those reporting no pain, subjects with widespread pain were more likely to be females (47.7% and 59.9%, respectively,  $P=0.00$ ) and older (mean age: 56.0 and 64.7, respectively;  $P=0.00$ ). The majority of subjects were white ( $n=4270$ , 95.9%) and there were no statistically significant differences in ethnicity between pain groups.

Overall, 4344 subjects contributed 30440 person-years of follow-up to the study. Follow-up ranged from 0.4 to 8.3 yrs. As shown in Table 2, those subjects who initially reported no pain

TABLE 2. Pain status and subsequent all-cause mortality risk

Pain status	Number in group	Person-years of follow-up	Number of deaths	Rate <sup>a</sup>	Crude		Adjusted			
					MRR	(95% CI) <sup>b</sup>	MRR <sup>b</sup>	(95% CI) <sup>b</sup>	MRR <sup>c</sup>	(95% CI) <sup>b</sup>
No pain	1993	14 308	389	27.2	Referent	–	Referent	–	Referent	–
Regional pain	1590	10 954	411	37.5	1.9	1.6, 2.3	1.2	1.02, 1.4	1.2	1.01, 1.4
Widespread pain	761	5178	217	41.9	2.4	1.9, 2.9	1.3	1.1, 1.5	1.3	1.1, 1.5

<sup>a</sup>Per 1000 person-years. <sup>b</sup>Adjusted for age, sex, practice and ethnic group. <sup>c</sup>Plus adjustment for Townsend score.

TABLE 3. Pain status and subsequent mortality risk: specific cause of death

Cause of death	ICD-10 rubric	Number of deaths	Crude				Adjusted			
			Regional pain		Widespread pain		Regional pain		Widespread pain	
			MRR	95% CI	MRR	95% CI	MRR <sup>a</sup>	95% CI	MRR <sup>a</sup>	95% CI
All cancers	C00-D48	228	2.1	1.5, 3.1	3.0	1.9, 4.5	1.3	0.98, 1.8	1.8	1.3, 2.6
Cardiovascular disease	I00-I99	478	2.1	1.6, 2.6	2.7	2.0, 3.6	1.1	0.93, 1.6	1.3	0.99, 1.6
Respiratory disease	J00-J99	174	1.4	0.9, 2.0	1.8	1.1, 2.7	0.8	0.6, 1.1	1.0	0.7, 1.6
All external causes	V01-Y09	12	1.4	0.4, 4.9	1.3	0.2, 7.3	0.8	0.2, 3.1	0.6	0.1, 3.8
Other	– <sup>b</sup>	126	1.8	1.1, 2.8	1.6	0.9, 2.9	1.0	0.7, 1.4	0.8	0.5, 1.4

<sup>a</sup>Adjusted for age, sex, Townsend score, practice and ethnic group. Subjects with no pain are the referent group for all analyses. <sup>b</sup>All other codes excluding those listed above.

had the lowest mortality rate (27.2/1000 person-years), followed by those with regional pain (37.5/1000 person-years) while those with widespread pain had the highest mortality rate (41.9/1000 person-years).

The overall rate of mortality in our study population was similar to that of the North West of England (SMR = 1.05; 95% CI 0.99, 1.12). When we examined the standardized rate stratified by pain status we found a similar mortality experience among those subjects reporting no pain (SMR = 1.03; 95% CI 0.96, 1.10). However, reporting regional pain (SMR = 1.10; 95% CI 0.95, 1.27) or widespread pain (SMR = 1.14; 95% CI 0.99, 1.30) was associated with an elevated all-cause mortality risk.

After adjusting for the effects of age, gender, Townsend score and ethnicity, the weighted analysis showed that subjects with regional pain were 20% and those with widespread pain 30% more likely to die over the 8-yr follow-up period when compared with those with no pain. When we examined the relationship between pain status at baseline and subsequent cause-specific mortality (Table 3) regional pain was associated with an elevated mortality risk from cancer (MRR = 1.3; 95% CI 0.98, 1.8) but not cardiovascular disease (MRR = 1.1; 95% CI 0.93, 1.6). Subjects with widespread pain had an elevated risk of deaths from cancer (MRR = 1.8; 95% CI 1.3, 2.6) and cardiovascular disease (MRR = 1.3; 95% CI 0.99, 1.6), although the latter relationship was not statistically significant. We hypothesized that these relationships were explained by pain arising from comorbid disease at the time of questionnaire completion. However, when we excluded those subjects who had died during the first year of follow-up the relationship with widespread pain remained unchanged for both cancer and cardiovascular deaths. The small number of deaths attributable to specific cancer sites prohibited a more detailed analysis. Pain status was not associated with deaths from any other cause. We then examined the relationship between the total pain score and cause-specific mortality. An increasing number of pain sites was associated with both cancer (MRR = 1.06; 95% CI 1.01, 1.1) and cardiovascular (MRR = 1.02; 95% CI 0.99, 1.1) deaths.

## Discussion

We have previously reported an increased mortality rate in subjects who reported regional and widespread pain in a community-based study of pain [11]. In that report, the excess mortality was almost entirely due to deaths from cancer. We have replicated those findings in a large population in the current study,

lending support to our original observation. We have also observed an increased risk of cardiovascular mortality that we had not observed in our previous study, although that relationship did not reach statistical significance after adjustment was made for putative confounding factors. On examination of the relationship between these specific causes of death we found that the risk of death increased as the number of reported pain sites increased.

Although these results replicate our previous findings of cancer-related mortality in a separate cohort of subjects, we have not necessarily identified incident cases of cancer. One could argue that the musculoskeletal pain reported at baseline may be symptomatic of underlying disease, i.e. cancer, and that it is unsurprising to observe the relationship. If that were true we would expect that the relationship would primarily be evident during the immediate period of follow-up. However, this was not the case as the relationship was proportional across all years of follow-up and persisted after excluding those subjects who had died during the first year of follow-up. In addition, we have previously demonstrated that widespread pain is associated with both cancer incidence and, following cancer onset, reduced survival [11].

There have been relatively few studies that have examined the mortality experience of persons with regional or widespread pain disorders. A clinic-based study [14] explored the cancer incidence experience of 1353 patients (1269 women, 84 men) referred to secondary care with 'possible' fibromyalgia. Of those, 1189 (88%) cases satisfied the ACR criteria [1], 131 (10%) did not fulfil criteria, while medical records were unavailable for 33 (2%) subjects. There was an increased risk of cancer among women (standardized incidence ratio = 1.4; 95% CI 1.1, 1.9) although these analyses were based on a small number of cancers ( $n = 50$ ). In a cohort study, fibromyalgia patients who satisfied the ACR criteria were found to have an increased risk of all-cause mortality (SMR = 1.5; 95% CI 1.2, 1.9) and specifically accidental deaths (SMR = 4.5; 95% CI 2.0, 10.1), infections (SMR = 4.5; 95% CI 1.7, 11.9) and pneumonia (SMR = 3.3; 95% CI 1.2, 8.8) over 25 yrs of follow-up [20]. A population-based study reported a higher 10-yr mortality rate among persons with fibromyalgia (22.6/1000 person-years) when compared to those without fibromyalgia (16.6/1000 person-years) [21]. The difference in mortality rates was not significant when adjusted for age and gender using a proportional hazards model. However, this analysis was based on only 54 subjects with fibromyalgia and 12 deaths over the study period. In a population-based study of women, reporting 'any' [odds ratio (OR) = 1.1; 95% CI 0.9, 1.4] or 'chronic' (OR = 1.01; 95% CI 0.8, 1.3) pain [12], symptoms were

not associated with increased all-cause mortality. Women with chronic chest pain had an increased all-cause mortality (OR = 1.75; 95% CI 1.2, 2.6). The authors were unable to identify and explore the relationship among subjects with widespread pain although reporting pain at regional sites was associated with an increased risk of developing cancer: head (OR = 1.5; 95%CI 1.03, 2.2) and abdominal (OR = 1.6; 95%CI 1.01, 2.4) pain.

More recently, we explored the mortality experience among subjects reporting 'widespread pain' (reporting pain in four or more joints) in a population-based cohort study conducted in Finland [13]. Overall, the risk of death was not increased among those with 'widespread pain' (relative risk = 0.9; 95% CI 0.7, 1.00). This discrepancy with our original and current observation could be explained by the different populations studied, the different aetiological processes by which these two populations may come to have widespread pain and the associated comorbidities. It is less important that the studies were conducted in rural vs urban areas, but more important that the factors associated with the presence of symptoms are likely to differ. Thus, in the Finnish study we could hypothesize that reports of widespread pain are more likely to be associated with mechanical factors and in the UK study with psychological factors. That alone would not be important; however, it may also be the case that the two populations also have different factors associated with the presence of widespread pain—for example, low physical activity that may explain the increase in mortality.

It is important to note that there may be unmeasured factors including smoking and morbidity at the time of survey completion, that may be independently associated with regional and widespread pain and cancer mortality, and that may act to confound the relationship we have observed. However, we have previously adjusted the relationship for the possible confounding effects of socioeconomic status, smoking and levels of psychological distress [10], and in the current study for ethnic group and found that the relationship persisted.

The replication of a relationship between musculoskeletal pain and mortality should encourage the investigation of the mechanism of association, and in particular the determination of whether premature mortality can be avoided. The relationship is with both regional and widespread pain. We have also reported a novel observation of an increasing risk of mortality with an increasing number of pain sites reported suggesting a dose-response relationship. We have previously proposed a number of mechanisms that may explain this observation [11] including the influence of insulin-like growth factor-1 and low levels of physical exercise. In our previous report, widespread pain was most strongly associated with female breast and prostate cancer and both cancers are associated with low levels of physical exercise. We have reported in this study a moderate relationship with cardiovascular mortality, an outcome that is also associated with reduced physical activity levels. The interesting question arises whether the onset of regional and widespread pain leads to long-term reduced levels of physical exercise that ultimately lead to an increased risk of cancer and cardiovascular mortality. One could hypothesize a negative correlation between an increasing number of pain sites reported and levels of physical activity that may lead to an increased mortality risk. Studies are under way to help elucidate possible mechanisms underlying these relationships.

### Rheumatology key messages

- Chronic widespread pain is associated with an increased risk of mortality.
- Pain is associated with cancer and cardiovascular deaths.
- The mechanism of association is unclear.

### Acknowledgements

The authors would like to acknowledge the staff and patients of the GP practices who participated in, and the researchers who conducted the original study.

**Funding:** The research was funded by grant from the West Pennine Health Authority, The Department of Health Programme at the National Primary Care Research and Development Centre, Universities of Manchester, Salford and York, and the Arthritis Research Campaign (grant reference no. 17552), Chesterfield, UK.

**Disclosure statement:** The authors have declared no conflicts of interest.

### References

- 1 Wolfe F, Smythe HA, Yunus MB, Bennett R, Bombardier C. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. *Arthritis Rheum* 1990;33:160–72.
- 2 Al-Alaf AW, Dunbar KL, Hallum NS, Nosratzadeh B, Templeton KD, Pullar T. A case-control study examining the role of physical trauma in the onset of fibromyalgia syndrome. *Rheumatology* 2002;41:450–3.
- 3 Gursoy S. Absence of association of the serotonin transporter gene polymorphism with the mentally healthy subset of fibromyalgia patients. *Clin Rheumatol* 2002;21:194–7.
- 4 Gursoy S, Erdal E, Herken H, Madenci E, Alasehirli B, Erdal N. Significance of catechol-O-methyltransferase gene polymorphism in fibromyalgia syndrome. *Rheumatol Int* 2003;23:104–7.
- 5 Frank B, Niesler B, Bondy B *et al*. Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients. *Clin Rheumatol* 2004;23:338–44.
- 6 McBeth J, Macfarlane GJ, Benjamin S, Silman AJ. Features of somatization predict the onset of chronic widespread pain: results of a large population-based study. *Arthritis Rheum* 2001;44:940–6.
- 7 Macfarlane GJ, Thomas E, Papageorgiou AC, Schollum J, Croft PR, Silman AJ. The natural history of chronic pain in the community: a better prognosis than in the clinic? *J Rheumatol* 1996;23:1617–20.
- 8 Kennedy M, Felson DT. A prospective long-term study of fibromyalgia syndrome. *Arthritis Rheum* 1996;39:682–5.
- 9 Penrod JR, Bernatsky S, Adam V, Baron M, Dayan N, Dobkin PL. Health services costs and their determinants in women with fibromyalgia. *J Rheumatol* 2004;31:1391–8.
- 10 Macfarlane GJ, McBeth J, Silman AJ. Widespread body pain and mortality: prospective population based study. *Br Med J* 2001;323:662–5.
- 11 McBeth J, Silman AJ, Macfarlane GJ. Association of widespread body pain with an increased risk of cancer and reduced cancer survival: a prospective, population-based study. *Arthritis Rheum* 2003;48:1686–92.
- 12 Smith BH, Elliott AM, Hannaford PC. Pain and subsequent mortality and cancer among women in the Royal College of General Practitioners Oral Contraception Study. *Br J Gen Pract* 2003;53:45–6.
- 13 Macfarlane GJ, Jones GT, Knekt P *et al*. Is the report of widespread body pain associated with long-term increased mortality? Data from the Mini-Finland Health Survey. *Rheumatology* 2007;46:805–7.
- 14 Dreyer L, Mellekjær L, Kendall S, Jensen B, Danneskiold-Samsøe B, Bliddal H. Increased cancer risk in patients referred to hospital with suspected fibromyalgia. *J Rheumatol* 2007;34:201–6.
- 15 Webb R, Brammah T, Lunt M, Urwin M, Allison T, Symmons D. Opportunities for prevention of 'clinically significant' knee pain: results from a population-based cross sectional survey. *J Public Health* 2004;26:277–84.
- 16 Urwin M, Symmons D, Allison T *et al*. Estimating the burden of musculoskeletal disorders in the community: the comparative prevalence of symptoms at different anatomical sites, and the relation to social deprivation. *Ann Rheum Dis* 1998;57:649–55.
- 17 Townsend P, Phillimore P, Beattie A. Health and deprivation: inequalities and the North. London: Croom Helm; 1988.
- 18 World Health Organization. ICD-10: international statistical classification of diseases and related health problems. Geneva: World Health Organization, 1992.
- 19 Stata Statistical Software. Stata. [Release 8.0]. 2003. TX: Stata Corporation.
- 20 Wolfe F, Hawley DJ, Anderson J. The long-term outcomes of fibromyalgia: rates and predictors of mortality in fibromyalgia after 25 years follow-up. *Arthritis Rheum* 1999;42:395.
- 21 Makela M, Heliovaara M. Prevalence of primary fibromyalgia in the Finnish population. *Br Med J* 1991;303:216–9.

# Are you using a treatment that addresses all 6 key manifestations of PsA?

The key clinical manifestations of PsA are joints, axial, skin, enthesitis, dactylitis and nails.<sup>1</sup>



## Joint relief in PsA:

**68%** of patients achieved **ACR50** with Cosentyx® (secukinumab) at **Year 1** (observed data)<sup>2</sup>

Results from ULTIMATE (N=166). The primary endpoint of GLOESS mean change from baseline vs placebo at Week 12 was met (-9 vs -6, p=0.004)<sup>2,3</sup>



## Skin clearance in PsO:

**55%** of patients achieved **PASI100** at **Week 52** with Cosentyx 300 mg AI (secondary endpoint, observed data, N=41)<sup>4</sup>

Results from MATURE. The co-primary endpoints PASI 75 and IGA mod 2011 0/1 at Week 12 were met for Cosentyx 300 mg (N=41) vs placebo (N=40), (95% vs 10% and 76% vs 8% respectively, p<0.0001)<sup>4</sup>



## Axial joint relief in PsA:

**69%** of patients achieved **ASAS40** at **Week 52** with Cosentyx 300 mg (secondary endpoint, observed data, N=139)<sup>1</sup>

Results from MAXIMISE. The primary endpoint of ASAS20 with Cosentyx 300 mg (N=164) vs placebo (N=164) at Week 12 was met (63% vs 31% respectively, p<0.0001)<sup>1</sup>



**Click here to visit our HCP portal and learn more**

**Cosentyx is the first and only, fully human biologic that directly blocks IL-17A regardless of its source<sup>5-10</sup>**



**A consistent safety profile with over 8 years of real-world experience<sup>5,6,11</sup>**

The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis).<sup>5,6</sup>

**Cosentyx licensed indications in rheumatology:** Cosentyx is indicated for the treatment of active psoriatic arthritis in adult patients (alone or in combination with methotrexate) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; moderate to severe plaque psoriasis in children and adolescents from the age of 6 years, and adults who are candidates for systemic therapy; active enthesitis-related arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate conventional therapy; active juvenile psoriatic arthritis in patients 6 years or older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.<sup>5,6</sup>

ULTIMATE (N=166), a multicentre, randomised, double-blind, placebo-controlled, 52-week Phase III trial in patients with PsA. Patients were randomly assigned to receive either weekly subcutaneous Cosentyx (300 mg or 150 mg according to the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The primary outcome of mean change in the ultrasound GLOESS from baseline to Week 12 was met (-9 vs -6; p=0.004).<sup>2,3</sup>

MATURE (N=122), a 52-week, multicentre, double-blind, randomised, placebo-controlled, Phase III trial in patients with PsO. Eligible patients were randomised to Cosentyx 300 mg or placebo. The co-primary endpoints were PASI75 and IGA mod 2011 0/1 responses at Week 12. The study met the co-primary endpoints: PASI75 and IGA mod 2011 0/1 response at Week 12 were met for Cosentyx 300 mg vs placebo (95% vs 10% and 76% vs 8% respectively, p<0.0001).<sup>4</sup>

MAXIMISE (N=498) a double blind, placebo-controlled, multicentre, Phase IIIb study in patients with PsA. Patients were randomised in a 1:1:1 ratio to receive Cosentyx 300 mg, 150 mg or placebo. The primary endpoint of the proportion of patients achieving and ASAS20 response with Cosentyx 300 mg at Week 12 vs placebo was met (63% vs 31% respectively, p<0.0001).<sup>1</sup>

ACR, American College of Rheumatology; AI, auto-injector; ASAS, Assessment of SpondyloArthritis International Society; BASDAI, Bath; ankylosing spondylitis disease activity index; EULAR, European Alliance of Associations for Rheumatology; GLOESS, Global EULAR and OMERACT synovitis score; IGA mod 2011 0/1, investigator global assessment modified 2011 0/1; OMERACT, outcome measures in rheumatology; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; PsO, plaque psoriasis.

**References:** 1. Baraliakos X, et al. *RMD open* 2019;5:e001005; 2. Conaghan PG, et al. Poster 253. *Rheumatology* 2022;61(Suppl1). DOI:10.1093/rheumatology/keac133.252; 3. D'Agostino MA, et al. *Rheumatology* 2022;61:1867-1876; 4. Sigurgeirsson B, et al. *Dermatol Ther* 2022;35(3):e15285; 5. Cosentyx® (secukinumab) GB Summary of Product Characteristics; 6. Cosentyx® (secukinumab) NI Summary of Product Characteristics; 7. Lynde CW, et al. *J Am Acad Dermatol* 2014;71(1):141-150; 8. Fala L. *Am Health Drug Benefits* 2016;9(Special Feature):60-63; 9. Schön M & Erpenbeck L. *Front Immunol* 2018;9:1323; 10. Gorelick J, et al. *Practical Dermatol* 2016;12:35-50; 11. European Medicines Agency. European public assessment report. Medicine overview. Cosentyx (secukinumab). Available at: [https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview\\_en.pdf](https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview_en.pdf) [Accessed May 2024].

Prescribing information, adverse event reporting and full indication can be found on the next page.

## **Cosentyx® (secukinumab) Great Britain Prescribing Information.**

### **Please refer to the Summary of Product Characteristics (SmPC) before prescribing.**

**Indications:** Treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. **Presentations:** Cosentyx 75 mg solution for injection in pre-filled syringe; Cosentyx 150 mg solution for injection in pre-filled syringe; Cosentyx 150 mg solution for injection in pre-filled pen; Cosentyx 300 mg solution for injection in pre-filled pen. **Dosage & Administration:** Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Consider discontinuation if no response after 16 weeks of treatment. Each 75 mg dose is given as one injection of 75 mg. Each 150 mg dose is given as one injection of 150 mg. Each 300 mg dose is given as two injections of 150 mg or one injection of 300 mg. If possible avoid areas of the skin showing psoriasis. **Plaque Psoriasis:** Adult recommended dose is 300 mg. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher. Adolescents and children from the age of 6 years: if weight  $\geq$  50 kg, recommended dose is 150 mg (may be increased to 300 mg as some patients may derive additional benefit from the higher dose). If weight < 50 kg, recommended dose is 75 mg. **Psoriatic Arthritis:** For patients with concomitant moderate to severe plaque psoriasis see adult plaque psoriasis recommendation. For patients who are anti-TNF $\alpha$  inadequate responders, the recommended dose is 300 mg, 150 mg in other patients. Can be increased to 300 mg based on clinical response. **Ankylosing Spondylitis:** Recommended dose 150 mg. Can be increased to 300 mg based on clinical response. **nr-axSpA:** Recommended dose 150 mg. **Enthesitis-related arthritis and juvenile psoriatic arthritis:** From the age of 6 years, if weight  $\geq$  50 kg, recommended dose is 150 mg. If weight < 50 kg, recommended dose is 75 mg. **Hidradenitis suppurativa:**

## **Cosentyx® (secukinumab) Northern Ireland Prescribing Information.**

### **Please refer to the Summary of Product Characteristics (SmPC) before prescribing.**

**Indications:** Treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. **Presentations:** Cosentyx 150 mg solution for injection in pre-filled pen; Cosentyx 300 mg solution for injection in pre-filled pen. **Dosage & Administration:** Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Consider discontinuation if no response after 16 weeks of treatment. Each 150 mg dose is given as one injection of 150 mg. Each 300 mg dose is given as two injections of 150 mg or one injection of 300 mg. If possible avoid areas of the skin showing psoriasis. **Plaque Psoriasis:** Adult recommended dose is 300 mg monthly. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher. Adolescents and children from the age of 6 years: if weight  $\geq$  50 kg, recommended dose is 150 mg (may be increased to 300 mg as some patients may derive additional benefit from the higher dose). If weight < 50 kg, recommended dose is 75 mg. However, 150mg solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Psoriatic Arthritis:** For patients with concomitant moderate to severe plaque psoriasis see adult plaque psoriasis recommendation. For patients who are anti-TNF $\alpha$  inadequate responders, the recommended dose is 300 mg, 150 mg in other patients. Can be increased to 300 mg based on clinical response. **Ankylosing Spondylitis:** Recommended dose 150 mg. Can be increased to 300 mg based on clinical response. **nr-axSpA:** Recommended dose 150 mg. **Enthesitis-related arthritis and juvenile psoriatic arthritis:** From the age of 6 years, if weight  $\geq$  50 kg, recommended dose is 150 mg. If weight < 50 kg, recommended dose is 75 mg. However, 150mg solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Contraindications:** Hypersensitivity to the active substance or excipients. Clinically important, active infection. **Warnings & Precautions:** **Infections:** Potential to increase risk of infections; serious infections have been observed. Caution in patients with chronic infection or history of recurrent infection. Advise patients to seek medical advice if signs/symptoms of infection occur. Monitor patients with serious infection closely and do not administer Cosentyx until the infection resolves. Non-serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies. Should not be given to patients with active tuberculosis (TB). Consider anti-tuberculosis therapy before starting Cosentyx in patients with latent TB. **Inflammatory bowel disease (including Crohn's disease and ulcerative colitis):** New cases or exacerbations of inflammatory bowel disease have been reported with secukinumab. Secukinumab, is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, secukinumab should be discontinued and appropriate medical management should be initiated. **Hypersensitivity reactions:** Rare cases of anaphylactic reactions have been observed. If an anaphylactic or serious allergic reactions occur, discontinue immediately and initiate appropriate therapy. **Vaccinations:** Do not give live vaccines concurrently with Cosentyx; inactivated or non-live vaccinations may be given. Paediatric patients should receive all age appropriate immunisations before treatment with Cosentyx. **Latex-Sensitive Individuals:** The removable needle cap of the 150mg pre-filled pen contains a derivative of natural rubber latex. **Concomitant immunosuppressive therapy:** Combination with immunosuppressants, including biologics, or phototherapy has not been evaluated in psoriasis studies. Cosentyx was given concomitantly with methotrexate, sulfasalazine and/or corticosteroids in arthritis studies. Caution when considering concomitant use of other immunosuppressants. **Interactions:** Live vaccines should not be given concurrently with secukinumab. No interaction between Cosentyx and midazolam (CYP3A4 substrate) seen in adult psoriasis study. No interaction between Cosentyx and methotrexate and/or corticosteroids seen in arthritis studies. **Fertility, pregnancy and lactation:** **Women of childbearing potential:** Use an effective method of contraception during and for at least 20 weeks after treatment. **Pregnancy:** Preferably avoid use of Cosentyx in pregnancy. **Breast feeding:** It is not known if secukinumab is excreted in human breast milk. A clinical decision should be made on continuation of breast feeding during Cosentyx treatment (and up to 20 weeks after discontinuation) based on benefit of breast feeding to the child and benefit of Cosentyx therapy to the

woman. **Fertility:** Effect on human fertility not evaluated. **Adverse Reactions:** **Very Common ( $\geq$ 1/10):** Upper respiratory tract infection. **Common ( $\geq$ 1/100 to <1/10):** Oral herpes, headache, rhinorrhoea, diarrhoea, nausea, fatigue. **Uncommon ( $\geq$ 1/1,000 to <1/100):** Oral candidiasis, lower respiratory tract infections, neutropenia, inflammatory bowel disease. **Rare ( $\geq$ 1/10,000 to <1/1,000):** anaphylactic reactions, exfoliative dermatitis (psoriasis patients), hypersensitivity vasculitis. **Not known:** Mucosal and cutaneous candidiasis (including oesophageal candidiasis). **Infections:** Most infections were non-serious and mild to moderate upper respiratory tract infections, e.g. nasopharyngitis, and did not necessitate treatment discontinuation. There was an increase in mucosal and cutaneous (including oesophageal) candidiasis, but cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections occurred in a small proportion of patients (0.015 serious infections reported per patient year of follow up). **Neutropenia:** Neutropenia was more frequent with secukinumab than placebo, but most cases were mild, transient and reversible. Rare cases of neutropenia CTCAE Grade 4 were reported. **Hypersensitivity reactions:** Urticaria and rare cases of anaphylactic reactions were seen. **Immunogenicity:** Less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment. **Other Adverse Effects:** The list of adverse events is not exhaustive, please consult the SmPC for a detailed listing of all adverse events before prescribing. **Legal Category:** POM. **MA Number & List Price:** PLGB 00101/1205 – 75 mg pre-filled syringe x 1 – £304.70; PLGB 00101/1029 – 150 mg pre-filled pen x2 £1,218.78; PLGB 00101/1030 – 150 mg pre-filled syringe x2 £1,218.78; PLGB 00101/1198 – 300 mg pre-filled pen x 1 £1218.78. **PI Last Revised:** June 2023. Full prescribing information, (SmPC) is available from: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ. Telephone: (01276) 692255.

**UK I 290802 | June 2023**

#### **Adverse Event Reporting:**

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis via [uk.patientsafety@novartis.com](mailto:uk.patientsafety@novartis.com) or online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report).

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com)

is 75 mg. However, 150mg solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Hidradenitis suppurativa:** Recommended dose is 300 mg monthly. Based on clinical response, the maintenance dose can be increased to 300 mg every 2 weeks. **Contraindications:** Hypersensitivity to the active substance or excipients. Clinically important, active infection. **Warnings & Precautions:** **Infections:** Potential to increase risk of infections; serious infections have been observed. Caution in patients with chronic infection or history of recurrent infection. Advise patients to seek medical advice if signs/symptoms of infection occur. Monitor patients with serious infection closely and do not administer Cosentyx until the infection resolves. Non-serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies. Should not be given to patients with active tuberculosis (TB). Consider anti-tuberculosis therapy before starting Cosentyx in patients with latent TB. **Inflammatory bowel disease (including Crohn's disease and ulcerative colitis):** New cases or exacerbations of inflammatory bowel disease have been reported with secukinumab. Secukinumab, is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, secukinumab should be discontinued and appropriate medical management should be initiated. **Hypersensitivity reactions:** Rare cases of anaphylactic reactions have been observed. If an anaphylactic or serious allergic reactions occur, discontinue immediately and initiate appropriate therapy. **Vaccinations:** Do not give live vaccines concurrently with Cosentyx; inactivated or non-live vaccinations may be given. Paediatric patients should receive all age appropriate immunisations before treatment with Cosentyx. **Latex-Sensitive Individuals:** The removable needle cap of the 150mg pre-filled pen contains a derivative of natural rubber latex. **Concomitant immunosuppressive therapy:** Combination with immunosuppressants, including biologics, or phototherapy has not been evaluated in psoriasis studies. Cosentyx was given concomitantly with methotrexate, sulfasalazine and/or corticosteroids in arthritis studies. Caution when considering concomitant use of other immunosuppressants. **Interactions:** Live vaccines should not be given concurrently with secukinumab. No interaction between Cosentyx and midazolam (CYP3A4 substrate) seen in adult psoriasis study. No interaction between Cosentyx and methotrexate and/or corticosteroids seen in arthritis studies. **Fertility, pregnancy and lactation:** **Women of childbearing potential:** Use an effective method of contraception during and for at least 20 weeks after treatment. **Pregnancy:** Preferably avoid use of Cosentyx in pregnancy. **Breast feeding:** It is not known if secukinumab is excreted in human breast milk. A clinical decision should be made on

continuation of breast feeding during Cosentyx treatment (and up to 20 weeks after discontinuation) based on benefit of breast feeding to the child and benefit of Cosentyx therapy to the woman. **Fertility:** Effect on human fertility not evaluated. **Adverse Reactions:** **Very Common ( $\geq$ 1/10):** Upper respiratory tract infection. **Common ( $\geq$ 1/100 to <1/10):** Oral herpes, headache, rhinorrhoea, diarrhoea, nausea, fatigue. **Uncommon ( $\geq$ 1/1,000 to <1/100):** Oral candidiasis, lower respiratory tract infections, neutropenia, inflammatory bowel disease. **Rare ( $\geq$ 1/10,000 to <1/1,000):** anaphylactic reactions, exfoliative dermatitis (psoriasis patients), hypersensitivity vasculitis. **Not known:** Mucosal and cutaneous candidiasis (including oesophageal candidiasis). **Infections:** Most infections were non-serious and mild to moderate upper respiratory tract infections, e.g. nasopharyngitis, and did not necessitate treatment discontinuation. There was an increase in mucosal and cutaneous (including oesophageal) candidiasis, but cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections occurred in a small proportion of patients (0.015 serious infections reported per patient year of follow up). **Neutropenia:** Neutropenia was more frequent with secukinumab than placebo, but most cases were mild, transient and reversible. Rare cases of neutropenia CTCAE Grade 4 were reported. **Hypersensitivity reactions:** Urticaria and rare cases of anaphylactic reactions were seen. **Immunogenicity:** Less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment. **Other Adverse Effects:** The list of adverse events is not exhaustive, please consult the SmPC for a detailed listing of all adverse events before prescribing. **Legal Category:** POM. **MA Number & List Price:** EU/1/14/980/005 – 150 mg pre-filled pen x2 £1,218.78; EU/1/14/980/010 – 300 mg pre-filled pen x 1 £1218.78. **PI Last Revised:** May 2023. Full prescribing information, (SmPC) is available from: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ. Telephone: (01276) 692255.

**UK I 284832 | May 2023**

#### **Adverse Event Reporting:**

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Novartis via [uk.patientsafety@novartis.com](mailto:uk.patientsafety@novartis.com) or online through the pharmacovigilance intake (PVI) tool at [www.novartis.com/report](http://www.novartis.com/report)

If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [medinfo.uk@novartis.com](mailto:medinfo.uk@novartis.com)